A. Prat

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets

F. Barkhof, X. Montalban, P. Vermersch, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Speci fi c Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged E ffi cacy of Cladribine Tablets A MAGNIFY-MS Substudy

F. Barkhof, L. Leocani, X. Montalban, 2022 .

Specific alterations in NKG2D+ T lymphocytes in relapsing-remitting and progressive multiple sclerosis patients.

Elie Haddad, P. Duquette, C. Larochelle, 2023, Multiple sclerosis and related disorders.

Identification of SARS-CoV-2-specific immune alterations in acutely ill patients

D. Kaufmann, J. Cailhier, J. Richard, 2020, medRxiv.

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

H. Atkins, J. Lechner-Scott, M. Onofrj, 2023, JAMA neurology.

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis

F. Barkhof, L. Leocani, X. Montalban, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Disability accrual in primary and secondary progressive multiple sclerosis

L. Kappos, J. Lechner-Scott, M. Onofrj, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

Impact of aging on treatment considerations for multiple sclerosis patients

P. Duquette, C. Larochelle, N. Arbour, 2023, Frontiers in neurology.

Sclerosis Patients Cytotoxicity and Is Increased in Multiple B Cell-Derived IL-15 Enhances CD8 T Cell

P. Duquette, I. Ifergan, N. Arbour, 2014 .